Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

[1]  A. Avan,et al.  Clinical Significance and Prognosis Value of Wnt Signaling Pathway in Cervical Cancer , 2017, Journal of cellular biochemistry.

[2]  G. Esmat,et al.  Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon , 2017, Journal of gastroenterology and hepatology.

[3]  A. Avan,et al.  Therapeutic Potential of Targeting Wnt/β‐Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress , 2017, Journal of cellular biochemistry.

[4]  D. Schuppan,et al.  Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal , 2017, Gut.

[5]  D. J. Kim,et al.  Transplantation with autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial , 2016, Hepatology.

[6]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[7]  P. Newsome,et al.  Non-alcoholic fatty liver disease in 2016. , 2016, British medical bulletin.

[8]  H. Pavenstädt,et al.  Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog , 2016, Nature Reviews Nephrology.

[9]  M. Manns,et al.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. , 2016, The Lancet. Infectious diseases.

[10]  K. Reddy,et al.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.

[11]  T. Saibara,et al.  Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice , 2015, EBioMedicine.

[12]  Natalie J Torok,et al.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014 , 2015, Hepatology.

[13]  S. Monga.  β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. , 2015, Gastroenterology.

[14]  S. Friedman,et al.  Pathobiology of liver fibrosis: a translational success story , 2015, Gut.

[15]  Michael Kahn,et al.  Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.

[16]  E. Canalis.  Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches , 2013, Nature Reviews Endocrinology.

[17]  D. Schuppan,et al.  Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.

[18]  Christopher D. Williams,et al.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.

[19]  M. Kahn,et al.  Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. , 2011, Journal of the American Society of Nephrology : JASN.

[20]  C. Nguyên,et al.  Inhibition of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis , 2010, Proceedings of the National Academy of Sciences.

[21]  D. Thabut,et al.  Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. , 2010, Gastroenterology.

[22]  T. Alonzi,et al.  Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. , 2009, Gastroenterology.

[23]  William M. Lee,et al.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.

[24]  N. Afdhal,et al.  Diagnosis and quantitation of fibrosis. , 2008, Gastroenterology.

[25]  S. Terai,et al.  Improved Liver Function in Patients with Liver Cirrhosis After Autologous Bone Marrow Cell Infusion Therapy , 2006, Stem cells.

[26]  Hong Ma,et al.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Davis,et al.  Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect , 2003, Hepatology.

[28]  H. Yamauchi,et al.  Interferon alfa down‐regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice , 2003, Hepatology.

[29]  J. Iredale,et al.  Pathogenesis of liver fibrosis. , 1997, Clinical science.

[30]  C. Nguyên,et al.  A small molecule inhibitor of -cateninCREB-binding protein transcription , 2004 .

[31]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.